Deep Sternal Wound Tuberculosis with Hypo-gamma-globulinemia

Kazuki Hamada, Keiji Oishi, Sho Uehara, Ryo Suetsake, Yoshikazu Yamaji, Maki Asami-Noyama, Nobutaka Edakuni, Tsunahiko Hirano, Kenji Sakamoto, Tsuneo Matsumoto and Kazuto Matsunaga

Abstract:
A 44-year-old man was referred to our hospital for the treatment of a pulmonary and deep sternal wound tuberculosis infection, which is an extremely rare type of extrapulmonary tuberculosis. Laboratory testing revealed a serum immunoglobulin (Ig) G level of 286 mg/dL, IgA of 22 mg/dL and IgM of 13 mg/dL. We therefore diagnosed him with hypo-gamma-globulinemia. He was treated with anti-tuberculosis medications and intravenous immunoglobulin. At present, the tuberculosis has not relapsed in the past six years. It may be useful to assess the humoral immunity status in tuberculosis patients with a normal T cell function, and immunoglobulin therapy may be beneficial for protecting such patients from reactivation of tuberculosis.

Key words: deep sternal wound tuberculosis, extrapulmonary tuberculosis, hypo-gamma-globulinemia, humoral immunity, immunoglobulin therapy

(Intern Med 57: 2563-2566, 2018)
(DOI: 10.2169/internalmedicine.0617-17)

Introduction
Tuberculosis infection is a public health problem worldwide (1), and the incidence of tuberculosis remains higher in Japan than in other developed countries (2). As immunosuppressive therapy and human immune deficiency virus (HIV) infection have become more common, more patients are now at risk of extrapulmonary tuberculosis. Deep sternal wound tuberculosis infections after cardiac surgery are an extremely rare type of extrapulmonary tuberculosis (3-6). Common pathogens of deep wound infection after cardiac surgeries are Staphylococcus aureus, Escherichia coli and Enterobacter spp. (6). Only 15 patients with deep sternal wound tuberculosis after cardiac surgery have been reported worldwide (6). While tuberculosis patients have received attention for their cell-mediated immunity status (7), humoral immunity dysfunction, such as hypo-gamma-globulinemia, in tuberculosis protection has not been described.

We herein report a case of pulmonary and deep sternal wound tuberculosis, which is an extremely rare type of extrapulmonary tuberculosis, with hypo-gamma-globulinemia.

Case Report
A 44-year-old man was admitted to a community hospital with an ulcer on a sternotomy wound. He had undergone aortic valve replacement for infective endocarditis for which no pathogen had been identified the previous year. A sternal ulcer with pus was observed, and he was diagnosed with a deep sternal wound infection. Chest computed tomography (CT) at the time revealed tree-in-bud pattern opacities in the bilateral upper lobe (Fig. 1). His sputum smear findings for acid-fast bacilli (AFB) and commercial polymerase chain reaction (PCR) for Mycobacterium tuberculosis were positive. He was transferred to our hospital for the management of sputum smear-positive M. tuberculosis. Notably, his medical history included pneumococcal meningitis twice when he
was 41 and 42 years of age. He had no personal, social or family history of tuberculosis. This patient had no risk factors for tuberculosis.

He presented with productive cough. There was no history of night sweats or weight loss. On an examination, he appeared ill and had a fever of 38.0°C. His oxygen saturation was 98% on ambient air. There were no palpable cervical lymph nodes. His cardiovascular examination revealed a soft systolic murmur at the apex. A pulmonary examination demonstrated coarse crackles bilaterally. A sternal ulcer with pus was observed. Laboratory testing revealed a white blood cell count of 18,400 per mm³, lactate dehydrogenase of 321 IU/L and C-reactive protein of 13.1 mg/dL (Table). Chest radiograph showed micronodules in the bilateral lungs.

On the 1st hospital day, he was prescribed 4 anti-tuberculosis medications (isoniazid 300 mg, rifampicin 450 mg, ethambutol 750 mg, and pyrazinamide 1.2 g per day). On the 7th hospital day, he underwent surgery for the deep sternal wound infection and started negative pressure wound therapy, which promotes wound healing by removing fluid from open wounds. After being treated with anti-tuberculosis medications, the tree-in-bud appearance disappeared (Fig. 2). Not only his sputum culture but also his infected site culture showed that the patient was positive for M. tuberculosis, and the diagnosis of pulmonary and deep sternal wound M. tuberculosis was later confirmed. He had an uneventful postoperative course during his hospital stay. The patient became smear-negative on the 31st day after admission and was discharged from the hospital. He was treated with 4 anti-tuberculosis medications for 2 months, followed by 2 anti-tuberculosis medications (isoniazid 300 mg and rifampicin 450 mg per day) for 4 months.

Given the high incidence of infectious diseases (i.e. pneumococcal meningitis, infective endocarditis and tuberculosis), we assessed the presence of immunodeficiency diseases. Anti-human immunodeficiency virus (HIV) antibodies were negative. The serum level of immunoglobulin (Ig) G was 286 mg/dL, IgA was 22 mg/dL and IgM was 13 mg/dL. A flow cytometry analysis of peripheral blood lymphocytes showed the percentage of B cells to be 1.7%. Electrophoresis of serum protein showed a decreased gammaglobulin fraction of 5.1% (Table). The bone marrow was normal, and there was no evidence of malignancy in this case. Given these findings, we diagnosed the patient with hypo-gamma-globulinemia. To prevent the recurrence of infectious diseases, the patient was treated with intravenous human immunoglobulin therapy by a monthly 3-day course (300 mg/kg/day), which kept the serum immunoglobulin within the therapeutic range (around 600 to 800 mg/dL) (8). The patient followed an uneventful course and has been free of recurrence of infectious diseases for six years.

### Discussion

Based on his histories of severe bacterial infection and tuberculosis, we measured the serum Ig levels in this patient and diagnosed him with hypo-gamma-globulinemia. Antibodies are essential for protection against Streptococcus pneumoniae, a common pathogen of bacterial meningitis, as in the present case. This is compatible with the fact that this patient had hypo-gamma-globulinemia.

We noted two important clinical issues concerning the present patient. First, it might be beneficial to assess the humoral immunity as well as the cell-mediated immunity status in tuberculosis patients. Second, immunoglobulin therapy in patients with hypo-gamma-globulinemia might help protect against the reactivation of tuberculosis.

Cell-mediated immunity is known to contribute to immunity against M. tuberculosis. Patients with HIV infection or who have been treated with anti-tumor necrosis factor-α monoclonal antibodies are at an increased risk to contract tuberculosis (7, 9). Although the role of B cells and antibodies in the defense against tuberculosis has not been described in detail, some cases have shown that a lack of anti-tuberculosis antibodies increases the risk of extrapulmonary tuberculosis. A case of endobronchial tuberculosis in X-linked agammaglobulinemia with intact cell-mediated immunity has been reported (10). Tuberculosis also developed in a patient with autosomal recessive hyper-IgM syndrome, which is characterized by an impaired humoral immunity. Children with humoral immune deficiency harboring defective antibodies against lipoolarabinomannan appear to have an increased risk of disseminated tuberculosis (11). A recent study showed that the IgA antibody titers against M. tuberculosis were associated with the status of tuberculosis patients (12). These reports suggest that humoral immune deficiency might increase the risk of developing tuberculosis. Some reports have revealed the mechanisms underlying the antibody activity to protect against tuberculosis. Antibodies against surface-expressed antigens opsonize tuberculosis and promote the Fc receptor-mediated phagocytosis of tuberculosis (13). Antibodies against tuberculosis augment the cell-mediated immunity through the activation of T cells, antigen presentation to CD4+ T cells and increased secretion of IL-12 and tumor necrosis factor (TNF)-α (14). Because tuberculosis is likely to develop in patients with an immunosuppressed status, tuberculosis patients should have not only their cell-mediated immunity but also their humoral immu-
In the present case, no severe infections occurred after immunoglobulin therapy, suggesting the potential efficacy of such therapy for preventing severe infections.

In conclusion, it might be beneficial in tuberculosis patients to assess the humoral immunity status, and intravenous immunoglobulin therapy might help prevent the reactivation of tuberculosis. Further reports should be accumulated to establish the role of humoral immunity in pulmonary tuberculosis and the efficiency of immunoglobulin therapy in preventing tuberculosis and severe wound infection in patients with humoral immunity deficiency.

The authors state that they have no Conflict of Interest (COI).

References

1. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
2. Tuberculosis in Japan -Annual report 2016. Tuberculosis Surveillance Center (2016). Department of Epidemiology and Clinical Research, the Research Institute of Tuberculosis, Tokyo, Japan (in Japanese).
3. Khan SA, Varshney MK, Hasan AS, Kumar A, Trīkha V. Tuberculosis of the sternum: a clinical study. J Bone Joint Surg Br 2010. 82: 1173-1178, 1996.
4. Wang TK, Wong CF, Au WK, Cheng VC, Wong SS. Mycobacterium tuberculosis sternal wound infection after open heart surgery: a case report and review of the literature. Diagn Microbiol Infect Dis 58: 245-249, 2007.
5. Zacharias A, Habib RH. Factors predisposing to median sternotomy complications. Deep vs superficial infection. Chest 110: 1173-1178, 1996.
6. Yuan SM. Sternal wound tuberculosis following cardiac operations: a review. Rev Bras Cir Cardiovasc 30: 489-493, 2015.
7. Rieder HL, Snider DE Jr, Caulden GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 141: 347-351, 1990.
8. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125: 1354-1360 e1354, 2010.
9. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with hypogamma-globulinemia might help prevent the reactivation of tuberculosis. Intern Med 57: 2563-2566, 2018 DOI: 10.2169/internalmedicine.0617-17.
infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.

10. Kawakami C, Inoue A, Takitani K, Kanegane H, Miyawaki T, Tamai H. X-linked agammaglobulinemia complicated with endobronchial tuberculosis. Acta Paediatr 100: 466-468, 2011.

11. Costello AM, Kumar A, Narayan V, et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans R Soc Trop Med Hyg 86: 686-692, 1992.

12. Niki M, Suzukawa M, Hoshino Y, et al. Evaluation of humoral immunity to Mycobacterium tuberculosis-specific antigens for correlation with clinical status and effective vaccine development. J Immunol Res 2015: 527395, 2015.

13. Maglione PJ, Xu J, Casadevall A, Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 180: 3329-3338, 2008.

14. Pethe K, Alonso S, Biet F, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412: 190-194, 2001.

15. Olivares N, Marquina B, Mata-Espinoza D, et al. The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation. Pathog Dis 69: 176-183, 2013.

16. Steele CL, Cridge C, Edgar JD. A novel treatment in X-linked agammaglobulinaemia - hyperbaric oxygen therapy in refractory chronic wounds. J Clin Immunol 34: 784-787, 2014.

17. Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 169: 172-181, 2012.

© 2018 The Japanese Society of Internal Medicine

Intern Med 57: 2563-2566, 2018